Skip to main content

Peer Review reports

From: Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

Original Submission
24 Jun 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
23 Jul 2022 Reviewed Reviewer Report
7 Aug 2022 Reviewed Reviewer Report - Hung-yu Huang
28 Aug 2022 Author responded Author comments - Yongchang Zhang
Resubmission - Version 5
28 Aug 2022 Submitted Manuscript version 5
Publishing
31 Aug 2022 Editorially accepted
5 Sep 2022 Article published 10.1186/s12885-022-10045-0

You can find further information about peer review here.

Back to article page